Mycrodose Therapeutics
Mycrodose Therapeutics is a San Diego-based biotech developing advanced drug delivery systems for psychedelic and controlled-substance therapeutics. One of only a few companies with DEA Schedule I research licences covering psilocybin, LSD, MDMA, and DMT, the company has demonstrated in vitro delivery of psilocin through human skin using a proprietary transdermal patch technology. A second programme involves an oral mucosa delivery system for ketamine targeting cancer-related mucositis. Mycrodose has completed an oversubscribed private placement to expand its patent portfolio.
Development Programmes
1Psilocybin Transdermal Patch
PsilocybinDepression / anxiety (transdermal delivery platform)
Programme Tracker
Major Depressive Disorder (MDD)
Company appears dormant/defunct since mid-2022; no clinical trials initiated; website domain redirected to unrelated mold removal service
Milestones
Funding milestone
CompletedActual: Sep 1, 2021
Oversubscribed seed round completed
Why it matters: Initial capitalization for transdermal delivery R&D. Company held DEA Schedule I license for psilocybin, LSD, MDMA, and DMT.
Company milestone
CompletedActual: Oct 1, 2021
LOI with Nova Mentis to co-develop psilocybin transdermal patch for Fragile X Syndrome / ASD
Why it matters: Partnership with Nova Mentis targeted a rare disease indication with potential orphan drug advantages. JV planned FDA clinical trials for Q1 2022 — never materialized.
Company milestone
CompletedActual: Mar 31, 2022
MDT-001 (ketamine sustained-release lozenge for oral mucositis) announced as first clinical candidate; IND meeting with FDA anticipated
Why it matters: Pivot from psilocybin patch to ketamine lozenge for oral mucositis — a supportive care indication in oncology. IND meeting was announced but never confirmed as occurring.
preclinical-data
CompletedActual: Apr 1, 2022
Successfully delivered both macro and microdose levels of psilocin through human skin in vitro using core drug delivery technologies
Why it matters: Proof-of-concept for transdermal psilocin delivery was achieved. However, in vitro skin permeation is a very early stage — significant formulation, stability, and in vivo work would be needed before clinical use.
Company milestone
CompletedActual: Jun 1, 2022
Last known public activity — no press releases, SEC filings, or news since mid-2022; website domain later redirected to mold removal service
Why it matters: Over 3.5 years of silence is a definitive signal the pharmaceutical operation is defunct or permanently paused. The Nova Mentis JV partner also went quiet after 2022. No clinical trials were ever initiated despite DEA and FDA approvals.
Recorded Events
Jun 1, 2022: Company milestone
Apr 1, 2022: preclinical-data
Mar 31, 2022: Company milestone
Oct 1, 2021: Company milestone
Sep 1, 2021: Funding milestone
Quick Facts
- Type
- Private Biotech
- Lead Stage
- Pre-clinical
- Website
- Visit